

PCT

Ref. of EP 00556800.7
 You: Ref. 2/A 00048-EP
 WORLD INTELLECTUAL PROPERTY ORGANIZATION
 International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

A61K 39/395, 38/17, 31/57, 31/445, 38/13
 // (A61K 39/395, 38/13) (A61K 39/395,
 31:57) (A61K 39/395, 31:445) (A61K
 38/17, 38:13) (A61K 38/17, 31:57) (A61K
 38/17, 31:445)

A1

(11) International Publication Number:

WO 98/52606

(43) International Publication Date: 26 November 1998 (26.11.98)

(21) International Application Number:

PCT/US98/10075

(22) International Filing Date:

15 May 1998 (15.05.98)

(30) Priority Data:

60/046,791	17 May 1997 (17.05.97)	US
60/049,389	11 June 1997 (11.06.97)	US
Not furnished	12 May 1998 (12.05.98)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	Not furnished (CON)
Filed on	12 May 1998 (12.05.98)
US	60/046,791 (CON)
Filed on	17 May 1997 (17.05.97)
US	60/049,389 (CON)
Filed on	11 June 1997 (11.06.97)

(71) Applicant (for all designated States except US): BIOGEN, INC.
 [-/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIRK, Allan, D.
 [-/US]; Madison, WI (US). HARLAN, David, M. [-/US];
 Bethesda, MD (US). THOMAS, David [-/US]; Houston,
 TX (US). KAUFFMAN, Michael [-/US]; Jamaica Plain,
 MA 02139-4618 (US). BURKLY, Linda [-/US]; West
 Newton, MA 02165 (US).

(74) Agent: FENTON, Gillian, M.; Biogen, Inc., 14 Cambridge
 Center, Cambridge, MA 02142 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
 GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
 TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO
 patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian
 patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
 patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,
 CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: USE OF A CD40:CD154 BINDING INTERRUPTOR TO PREVENT COUNTER ADAPTIVE IMMUNE RESPONSES,
 PARTICULARLY GRAFT REJECTION

(57) Abstract

Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interruptor, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interruptor and a CD28 signalling interruptor. An exemplary CD40:CD154 binding interruptor is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signalling interruptor is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KF	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF A CD40:CD154 BINDING INTERRUPTOR TO PREVENT COUNTER-ADAPTIVE IMMUNE RESPONSES, PARTICULARLY GRAFT REJECTION

Related Applications

This is a continuation-in-part of a U.S. Provisional patent application filed on May 12, 1998 (Docket No. A053P; Express Mail Label No. EM046582947US), as a continuation-in-part of prior U.S. Provisional S.N. 60/046,791, filed May 17, 1997 and of prior U.S. Provisional S.N. 60/049,389, filed June 11, 1997. The teachings of all three earlier-filed Provisional patent applications are incorporated herein by reference.

Field of the Invention

The invention relates generally to the suppression of unwanted immune responses, particularly of counter-adaptive T-lymphocyte mediated immune responses. The invention relates in particular to the prevention, treatment, suppression or reversal of immune-system driven rejection of grafted tissue or a grafted organ in a recipient host.

Background of the Invention

Organ transplantation between genetically non-identical individuals invariably results in immunological rejection of the organ through T cell dependent mechanisms, unless the rejection process is bridled by administering drugs that suppress T cell function. Several U.S. Patents disclose the use of such immunosuppressant drugs for inhibiting graft rejection, including U.S. Nos. 5,104,858; 5,008,246; and, 5,068,323. Other conventional agents are described in Suthanthiran et al. (1994), 331 New Eng. Med. J. 365-376. Both calcineurin phosphatase inhibitors and glucocorticosteroids are used clinically, and both prevent the T cell mediated release of activating cytokines, particularly IL-2. However, therapy with these types of conventional agents remains imperfect. Both types act by impairing signalling through the T cell antigen receptor (TCR), the sole mediator of T cell antigen specificity, and act on all T cells

indiscriminately. In addition, the effect of these drugs is not lasting, such that cessation of treatment generally results in graft loss. Thus, in order to maintain viable, functional integration of the graft, transplant recipients must suffer the consequences of long-term, non-specific immunosuppression. These consequences include an increased risk of infection and malignancy, as well as significant expense and toxicity.

There is accordingly a need for improved or more effective immunosuppressive or immunomodulatory treatments for graft recipients. In particular, there is a need for treatments that do not require pan-T cell immunosuppression, i.e., treatments that do not leave the recipient vulnerable to malignancies or opportunistic infection. More pointedly, there is a need for treatments that have lesser toxicity than currently available therapeutic agents. Similarly, there is a need for treatments that promote lasting functional integration of the graft, i.e., integration that persists beyond termination of the course of treatment.

Summary of the Invention

It is an object of this invention to provide an immunomodulatory agent that mitigates counter-adaptive T cell responses without the need for pan-T cell immunosuppression. Another object is to provide an immunomodulatory agent that promotes functional integration of a tissue graft in a recipient host. Another object is to provide an immunomodulatory agent that inhibits immunological rejection of grafted tissue. A further object is to provide an immunomodulatory agent that interrupts delivery of a costimulatory signal to activated T cells. A particular object is to provide a CD40:CD154 binding interruptor for use in therapy, particularly for use in therapy to mitigate or delay immunological rejection of grafted tissue. Another particular object is to provide a therapeutic composition and treatment regime for mitigating counter-adaptive T cell mediated immune responses, based on the use of a CD40:CD154 binding interruptor in combination with another immunosuppressant or immunomodulator. Thus, a specific object of the invention is to provide a therapeutic composition and treatment regime based on the use of a CD40:CD154 binding interruptor in combination with an agent that blocks costimulation via CD28. A more general object of the invention is to provide a therapeutic composition and

treatment regime for inhibiting, mitigating, attenuating, delaying or reversing failure or acute rejection of grafted tissue. Another general object of the invention is to improve the availability of tissue grafts, by providing immunomodulatory compositions that allow functional integration of allogeneic or xenogeneic tissue into a recipient host. A still further general object is to prevent, mitigate, attenuate or treat disease states resulting from a counter-adaptive immune response, including T-lymphocyte mediated autoimmune illnesses (e.g., insulin dependent diabetes mellitus, multiple sclerosis and the like), as well as allergic illnesses.

The present invention rests on the discovery that use of a CD40:CD154 binding interruptor, alone or in combination with another immunomodulatory agent, attenuates, suppresses, prevents, delays or reverses counter-adaptive immune system rejection of grafted tissue in a recipient host, *without* the need for pan-suppression of the recipient's immune system.

The invention accordingly provides methods and compositions for immunomodulatory therapy for recipients of grafted tissue. A first method inhibits rejection of a tissue graft by a graft recipient, by treating the graft recipient with a CD40:CD154 (CD40L) binding interruptor. The present binding interruptor is any agent that interrupts the binding of a costimulatory molecule (here, CD40 ligand, also referred to herein as the 5c8 antigen, CD40L, CD154, and also referred to in the art as gp39) to its counter or cognate receptor (here, CD40). Preferably, the binding interruptor is an anti-CD40L compound, by which is meant a compound that binds to CD40L (CD154) and thereby blocks, interferes with or disrupts the ability of CD40L to bind to CD40. An exemplary anti-CD40L compound is a monoclonal antibody, particularly an antibody having the antigen-specific binding characteristics of the 5c8 antibody disclosed in U.S. Patent 5,474,771, the teachings of which are incorporated herein by reference.

A second method prolongs survival of a tissue graft in a graft recipient, by treating the graft recipient with a CD40:CD154 binding interruptor, preferably with an anti-CD40L monoclonal antibody. A third method attenuates immunological complications of failure of grafted tissue, by treating a graft recipient with a CD40:CD154 binding interruptor, preferably with an anti-CD40L monoclonal antibody. That is, the method inhibits, suppresses, mitigates or detectably decreases such immunological complications. In particular, the method avoids or

mitigates complications such as interstitial fibrosis, chronic graft atherosclerosis, vasculitis and the like.

The foregoing methods thus are effective for treatments of acute and/or chronic rejection of grafted tissue, and can be used prophylactically, for post-operative treatment, or for reversing or suppressing graft rejection at any time during the recipient's lifetime. An exemplary method involves administration of a CD40:CD154 binding interruptor on postoperative days 2, 4, 6, 8, 12, 16 and 28. More generally, the methods described herein involve administration of the binding interruptor at desired intervals (daily, twice weekly, weekly or biweekly) over at least a two- or three-week period. The administration schedule is adjusted as needed to produce a detectable decrease in indicia of counter-adaptive immune responses, particularly indicia of graft rejection. The present treatment regime can be repeated in the event of a subsequent episode of graft rejection. In embodiments wherein the binding interruptor is an anti-CD40L monoclonal antibody, the interruptor is administered at doses between about 5 mg/kg body weight and about 20 mg/kg body weight.

For treatment, the CD40:CD154 binding interruptor can be formulated in a therapeutic composition which includes a therapeutically effective amount of the binding interruptor dispersed in a pharmaceutically acceptable carrier. In some embodiments, the therapeutic composition can also include a therapeutically effective amount of another immunosuppressive or immunomodulatory compound, including without limitation: an agent that interrupts T cell costimulatory signalling via CD28 (e.g., CTLA4Ig); an agent that interrupts calcineurin signalling (e.g., cyclosporine, a macrolide such as tacrolimus, formerly known as FK506); a corticosteroid; or an antiproliferative agent (e.g., azathioprine). Other therapeutically effective compounds suitable for use with the present CD40:CD154 binding interruptor include sirolimus (formerly known as rapamycin); mycophenolate mofetil (MMF), mizoribine, deoxyspergualin, brequinar sodium, leflunomide, azaspirane and the like.

The methods and compositions of the invention are suitable for use with all types of graft procedures. Thus, the invention is suitable for use where the graft recipient (recipient host) is a mammal, preferably a primate, most preferably a human. The graft donor may be a non-

syngeneic member of the same phylogenetic species as the graft recipient (i.e., an allogeneic donor, providing allograft tissue), or a member of a distinct phylogenetic species (i.e., a xenogeneic donor, providing xenograft tissue). If a xenogeneic donor is used as the graft tissue source, preferably the donor is relatively MHC-compatible with the recipient host; for example, a baboon or chimpanzee would be preferred as a donor for grafting tissue into a human. The invention can be used to promote engraftment of any body tissue or organ type, regardless of whether the donor (graft) tissue be an entire organ, section or portion of an organ or tissue, or isolated cells. Non-limiting examples of suitable tissues include renal, hepatic, cardiac, pancreatic (e.g., islet), skin, vascular, nerve, bone, cartilage and like mammalian body tissues.

As disclosed herein, the principles of the present invention have been validated by testing in a relevant preclinical model. An exemplary CD40:CD154 binding interruptor (the anti-CD40L monoclonal antibody 5c8) has been tested alone and in combination with other exemplary immunomodulators (the CD28 binding interruptor CTLA4-Ig; mycophenolate mofetil; corticosteroids; tacrolimus), on rhesus peripheral blood leukocytes in vitro, and in rhesus monkeys transplanted with primarily vascularized renal allografts.

The foregoing and other objects, features and advantages of the present invention, as well as the invention itself, will be more fully understood from the following description of preferred embodiments.

Detailed Description of the Invention

Data establishing that T cell activation requires both TCR mediated signals and simultaneously delivered costimulatory signals have accumulated over the past twenty years. For example, antibody production by B lymphocytes in response to protein antigens requires a specific, costimulatory interaction with T lymphocytes. This B cell/T cell interaction is mediated through several receptor-ligand binding events in addition to engagement of the TCR. These additional binding events include the binding of CD40 on B cells to CD154 (CD40L) on T cells. Human CD40 is a 50 kD cell surface protein expressed on mature B cells, as well as macrophages and activated endothelial cells. CD40 belongs to a class of receptors involved in

programmed cell death, including Fas/CD95 and the tumor necrosis factor (TNF) alpha receptor.

Human CD154 (CD40L) is a 32 kD type II membrane glycoprotein with homology to TNF alpha that is transiently expressed primarily on activated T cells. CD40:CD154 binding has been shown to be required for all T cell-dependent antibody responses. In particular, CD40:CD154 binding provides anti-apoptotic and/or lymphokine stimulatory signals.

Another important costimulatory signal is produced by the binding of CD28 on T cells to its counter receptor CD80 (B7-1) or CD86 (B7-2) on antigen presenting cells (APCs) and perhaps also on parenchymal cells. Significantly, CD80 and/or CD86 expression is upregulated by signals initiated on the binding of CD40 to CD154. Further studies have shown that the T cell molecule CTLA4 (CD152) appears to down-regulate costimulation and TCR mediated activation, at least in part by competing with CD28 for CD80/CD86, and by delivering a unique negative signal to the TCR signal transduction complex.

The importance of CD40:CD154 binding in promoting T cell dependent biological responses is underscored by the development of X-linked hyper-IgM syndrome (X-HIGM) in humans lacking functional CD154. These individuals have normal or high IgM levels, but fail to produce IgG, IgA or IgE antibodies. Affected individuals suffer from recurrent, sometimes severe, bacterial infection (most commonly with *Streptococcus pneumoniae* and *Hemophilus influenzae*) and certain unusual parasitic infections, as well as an increased incidence of lymphomas and abdominal cancers. These clinical manifestations of disease can be managed through intravenous immunoglobulin replacement therapy.

The effects of X-HIGM are simulated in animals rendered nullizygous for the gene encoding CD154 (knockout animals). Studies with nullizygotes have confirmed that, while B cells can produce IgM in the absence of CD40L:CD154 binding, they are unable to undergo isotype switching, or to survive normally after affinity maturation. In the absence of a functional CD40:CD154 interaction, lymph node germinal centers do not develop properly, and the development of memory B cells is impaired. These defects contribute to a severe reduction or absence of a secondary (mature) antibody response.

Individuals with X-HIGM and CD154 nullizygotes also have defects in cellular immunity. These defects are manifested by an increased incidence of *Pneumocystis carinii*, *Histoplasma capsulatum*, *Cryptococcus neoformans* infection, as well as chronic *Giardia lamblia* infection. Murine nullizygotes are deficient in their ability to fight *Leishmania* infection. Many of these cell-mediated defects are reversible by administration of IL-12 or IFN-gamma. These data substantiate the view that CD40:CD154 binding promotes the development of Type I T-helper cell responses. Further support is derived from the observation that macrophage activation is defective in CD154-deficient settings, and that administration of anti-CD40L antibodies to mice diminished their ability to clear *Pneumocystis* infection. Blockade of CD40:CD154 binding appears to reduce the ability of macrophages to produce nitric oxide, which mediates many of the macrophage's pro-inflammatory activities. It should be noted, however, that mammals (including humans) who lack functional CD154 do not develop significant incidences of viral infection or sepsis.

A number of preclinical studies have established that agents capable of interrupting CD40:CD154 binding have promise as immunomodulating agents. In murine systems, antibodies to CD154 block primary and secondary immune responses to exogenous antigens, both in vitro and in vivo. Antibodies to CD154 cause a reduction in germinal centers in mice and monkeys, consistent with data on CD154 immunodeficiency. Administration of three doses of anti-CD154 antibody to lupus-prone mice, aged three months, substantially reduced titers against double-stranded DNA and nucleosomes, delayed the development of severe nephritis, and reduced mortality. Moreover, administration of anti-CD154 antibodies to mice aged five to seven months with severe nephritis was shown to stabilize or even reverse renal disease. Anti-CD154 antibodies given concomitantly with small resting allogeneic lymphocytes permitted unlimited survival of mouse pancreatic islet autografts. In other animal models, interference with CD40:CD154 binding has been demonstrated to reduce symptoms of autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease), graft rejection (cardiac allograft, graft-versus-host disease), and mercuric chloride induced glomerulonephritis, which is mediated by both humoral and cellular mechanisms.

Additional studies in rodents have shown that T cell activation can be blocked, and rodent allograft survival prolonged, by interfering with the binding of CD80/CD86 to its T cell counter receptors, CD28 and CTLA4. These studies involved the use of the CD80/CD86 specific fusion protein, CTLA4-Ig, as a CD28 signalling interruptor. Others have demonstrated that CD80/CD86 up-regulation can be prevented by use of a CD40:CD154 binding interruptor (e.g., the monoclonal antibody MR1). Both classes of immunomodulatory agents appear to be dependent on TCR engagement for their effectiveness. Thus, such agents offer the capacity to modulate the specificity of T cell dependent biological processes, rather than depending on pan T cell immunosuppression. Studies involving the use of such agents in vivo in rodent models of graft rejection have produced dramatic results, including the acceptance of fully mismatched skin grafts, a result not obtainable with currently available immunosuppression.

It is noteworthy, however, that all previously reported studies of long-term graft survival in rodents have failed, or have been associated with unacceptable toxicity, when tested in other mammals, particularly primates.

Disclosed proof-of-principle studies of the present invention, by contrast, establish that use of a CD40:CD154 binding interruptor, alone or in combination with another immunomodulating or immunosuppressing agent (such as a CD28 signalling interruptor) promotes long-term, rejection free integration of heterologous (MHC-mismatched) donor tissue into a primate recipient. It is encouraging that the therapy disclosed herein was remarkably simple, involving the administration of therapeutic agents through a standard peripheral intravenous catheter, and was tolerated remarkably well by the recipients. This is in stark contrast to other regimens used to achieve lasting graft acceptance in primates, requiring ionizing radiation, administration of donor-derived bone marrow, and significant perioperative immunosuppression. The animals treated in studies described herein displayed no evidence of T cell activation or the cytokine release typically observed following treatment with antibodies directed at CD3, and prolonged survival has not been carried with it a demonstrable cost in terms of opportunistic infection. In addition, no alterations in peripheral blood hematological parameters were noted during these studies. Long-term survival was achieved without apparent clearing or

global reductions in any lymphocyte subset, and without loss of in vitro T cell responsiveness. It is therefore unlikely that the observed effect is attributable to T cell destruction following antibody or fusion protein opsonization. The results are striking. Success in outbred rhesus monkeys suggests that allograft (or even xenograft) integration is an achievable goal in humans, using this or an equivalent therapeutic approach.

The mechanism and relative contribution of each agent in the optional combination therapy described below remains unclear. The success of CD40:CD154 blockade alone suggests that any basal costimulation signalling is less important in maintaining the rejection response than CD80/CD86 upregulation. Indeed, anti-CD154 antibody administration resulted in impressive rejection-free survival when used alone, whereas the effects of the CD28 interruptor (the CTLA4-Ig) were more transient. Given that CD154 is expressed on non-myeloid cells, including vascular endothelium and smooth muscle, and that CD80 can be induced on fibroblasts and hepatocytes, non-T cell events may be critical in establishing reactivity against the donor tissue. By denying the immune system access to significant parenchymal adhesion and costimulatory signals at the time of transplantation, graft recognition and destruction may be prevented. The differences in activation induced by donor parenchyma and activation induced by lymphoid cells could explain the observed preservation of in vitro reactivity to donor lymphocytes despite normal graft function, and the general poor correlation between MLR reactivity and clinical graft outcome. Nonetheless, the effects of the exemplary costimulation blocking agents, CTLA4-Ig and humanized 5c8 (anti-human CD154), were shown to be synergistic both in vitro and in vivo. Perhaps, CTLA4-Ig provides insurance against CD80/CD86 expression that escapes the effects of CD40:CD154 binding interruption by humanized 5c8. In that instance, considerable time seems to be required to mount an effective acute rejection with the few cells that escape initial blockade.

As this strategy was successful in reversing established, biopsy proven rejection, it would appear that the rejection process must be maintained by continuous costimulation, rather than being a process that, once set into motion, proceeds unless the effector cells are eliminated or rendered incapable of TCR signaling. Teleologically, the body is best served by inflammation

that is easily controlled. Thus, in the absence of direction to attack, retreat may be the tacit order. This supports the view that exploitation of the immune system's natural propensity to down-regulate should be more advantageous than pan-immunosuppression.

The following discussion illustrates and exemplifies the variety of contexts and circumstances in which the invention can be practiced, as well as providing proof-of-principle studies involving specific embodiments of the invention.

Recipient Hosts

The invention can be used for treatment or prophylaxis of any mammalian recipient of a tissue graft, or any mammal in need of a tissue graft. Preferably, the recipient (also referred to herein as the recipient host, or simply the host) is a primate, more preferably a higher primate, most preferably a human. In other embodiments, the recipient may be another mammal in need of a tissue graft, particularly a mammal of commercial importance, or a companion animal or other animal of value, such as a member of an endangered species. Thus, recipient hosts also include, but are not limited to, sheep, horses, cattle, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats and mice.

Donor or Graft Tissue

The invention can be used with any type of tissue transplant or graft procedure, particularly procedures wherein the donor (grafted) tissue is affected by, or at risk of, failure or rejection by the recipient host's immune system. In particular, the invention can be used in any context wherein the donor tissue is not histocompatible with the recipient host. Thus, in addition to autologous or syngeneic donor tissue, the invention can be used with allogeneic or even xenogeneic donor tissue. The donor tissue can be derived, by conventional means, from a volunteer or other living donor, or from a cadaveric donor. Preferably, the donor is as histocompatible as practicable with the recipient host. Thus, where the recipient host is a human, autologous and allogeneic donor tissue is preferred. However, the donor tissue can be obtained

from a heterologous species (in which case it is referred to as a heterograft), such as a non-human primate (e.g., a chimpanzee or a baboon), or another relatively compatible mammal (e.g., a pig).

In some embodiments, the donor tissue comprises an organ or body part. In other embodiments, the donor tissue comprises a part, portion or biopsy of a donor organ or tissue. In still other embodiments, the donor tissue comprises cells, particularly isolated or suspended cells, including cells withdrawn or excised from a donor host, cells maintained in primary culture, or an immortalized cell line. Optionally, the donor tissue can include cells harboring exogenous genetic material, such as transfected or transformed host cells which have been (or are derived from ancestor cells which have been) engineered to include genetic material necessary for the production of a polypeptide of therapeutic value to the recipient host. In still other embodiments, the donor tissue can be derived from a transgenic mammal that has been engineered to include genetic material necessary for the production, in some or all of its body tissues, of a polypeptide of therapeutic value to the recipient host. Exemplary polypeptides of therapeutic value to the recipient include: hormones such as insulin or growth hormone; cytokines; growth and differentiation factors; enzymes; structural proteins; and the like.

Thus, in light of the foregoing, it is clear that the invention can be used with such solid organ grafts as: transplanted kidney, liver, pancreas, lung, heart, and the like. Similarly, the invention can be used with sections or portions of the foregoing as well as with additional tissue types, especially renal, hepatic, pancreatic (particularly islet), respiratory, cardiac, skin, vascular, nerve, bone, bone marrow, cartilage, tendon, ligament, muscle, fat, mammary, gastrointestinal lining, epithelium, endothelium, connective tissue, and the like. Furthermore, the invention can be used with body parts comprising multiple tissue types, such as for the replacement or other surgical alteration or reconstruction of an eye, ear, nose, digit (finger or toe), joint, blood vessel, nerve, muscle, limb, or other body part. In other embodiments, the invention can be used with a cell preparation or suspension, introduced systemically or locally into the recipient host. For example, isolated, suspended or dispersed cells can be infused intravascularly, or implanted into a desired site, such as a bone marrow cavity, the liver, within the kidney capsule or a joint capsule, intramuscularly, or applied locally to a wound site. Exemplary cells include peripheral

blood cells, bone marrow or any hematopoietic component thereof, mesenchymal stem cells, muscle satellite cells, hepatocytes, hormone-producing or neuroendocrine cells, fibroblasts, neural crest cells, endothelia, and the like. In some embodiments, the cells are mitotically competent and produce new tissue of donor origin. In other embodiments, the cells are not mitotically competent, but produce or express a polypeptide or other product of therapeutic value to the recipient.

Exemplary CD40:CD154 Interruptors

Therapeutic compounds useful for the methods of the invention include any compound that blocks the interaction of cell surface CD40 (e.g., on B cells) with CD40L (CD154) expressed on the surface of activated T cells. CD40:CD154 binding interruptor compounds, such as anti-CD40L compounds, that are specifically contemplated include polyclonal antibodies and monoclonal antibodies (mAbs), as well as antibody derivatives such as chimeric molecules, humanized molecules, molecules with reduced effector functions, bispecific molecules, and conjugates of antibodies. In a preferred embodiment, the antibody is 5c8, as described in U.S. Patent 5,474,771, the disclosure of which is hereby incorporated by reference. In a currently highly preferred embodiment, the antibody is a humanized 5c8. Other known antibodies against CD154 include antibodies ImxM90, ImxM91 and ImxM92 (obtained from Immunex), an anti-CD40L mAb commercially available from Ancell (clone 24-31, catalog # 353-020, Bayport, MN), and an anti-CD40L mAb commercially available from Genzyme (Cambridge, MA, catalog # 80-3703-01). Also commercially available is an anti-CD40L mAb from PharMingen (San Diego, catalog #33580D). Numerous additional anti-CD40L antibodies have been produced and characterized (see, e.g., WO 96/23071 of Bristol-Myers Squibb, the specification of which is hereby incorporated by reference).

The invention also includes anti-CD40L molecules of other types, such as complete Fab fragments, $F(ab')_2$ compounds, V_H regions, V_L regions, single chain antibodies (see, e.g., WO 96/23071), polypeptides, fusion constructs of polypeptides, fusions of CD40 (such as CD40Ig, as in Hollenbaugh et al., J. Immunol. Meth. 188:1-7, 1995, which is hereby incorporated by reference), and small molecule compounds such as small semi-peptidic compounds or

non-peptide compounds, all capable of blocking or interrupting CD40:CD154 binding. Procedures for designing, screening and optimizing small molecules are provided in the patent application PCT/US96/10664, filed June 21, 1996, the specification of which is hereby incorporated by reference.

Various forms of antibodies may also be produced using standard recombinant DNA techniques (Winter and Milstein, *Nature* 349: 293-99, 1991). For example, "chimeric" antibodies may be constructed, in which the antigen binding domain from an animal antibody is linked to a human constant domain (an antibody derived initially from a nonhuman mammal in which recombinant DNA technology has been used to replace all or part of the hinge and constant regions of the heavy chain and/or the constant region of the light chain, with corresponding regions from a human immunoglobulin light chain or heavy chain) (see, e.g., Cabilly et al., United States Pat. No. 4,816,567; Morrison et al., *Proc. Natl. Acad. Sci.* 81: 6851-55, 1984). Chimeric antibodies reduce the immunogenic responses elicited by animal antibodies when used in human clinical treatments.

In addition, recombinant "humanized" antibodies may be synthesized. Humanized antibodies are antibodies initially derived from a nonhuman mammal in which recombinant DNA technology has been used to substitute some or all of the amino acids not required for antigen binding with amino acids from corresponding regions of a human immunoglobulin light or heavy chain. That is, they are chimeras comprising mostly human immunoglobulin sequences into which the regions responsible for specific antigen-binding have been inserted (see, e.g., PCT patent application WO 94/04679). Animals are immunized with the desired antigen, the corresponding antibodies are isolated and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of the human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (inter-species) sequences in antibodies for use in human therapies, and are less likely to elicit unwanted immune responses. Primatized antibodies can be produced similarly.

Another embodiment of the invention includes the use of human antibodies, which can be produced in nonhuman animals, such as transgenic animals harboring one or more human immunoglobulin transgenes. Such animals may be used as a source for splenocytes for producing hybridomas, as is described in U.S. 5,569,825.

Antibody fragments and univalent antibodies may also be used in the methods and compositions of this invention. Univalent antibodies comprise a heavy chain/light chain dimer bound to the Fc (or stem) region of a second heavy chain. "Fab region" refers to those portions of the chains which are roughly equivalent, or analogous, to the sequences which comprise the Y branch portions of the heavy chain and to the light chain in its entirety, and which collectively (in aggregates) have been shown to exhibit antibody activity. A Fab protein includes aggregates of one heavy and one light chain (commonly known as Fab'), as well as tetramers which correspond to the two branch segments of the antibody Y, (commonly known as F(ab)₂), whether any of the above are covalently or non-covalently aggregated, so long as the aggregation is capable of selectively reacting with a particular antigen or antigen family.

In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a humanized antibody may be increased by mutagenesis based on molecular modeling (Queen et al., Proc. Natl. Acad. Sci. 86:10029-33, 1989; PCT patent application WO 94/04679). It may be desirable to increase or to decrease the affinity of the antibodies for CD40L, depending on the targeted tissue type or the particular treatment schedule envisioned. This may be done utilizing phage display technology (see, e.g., Winter et al., Ann. Rev. Immunol. 12:433-455, 1994; and Schier et al., J. Mol. Biol. 255:28-43, 1996, which are hereby incorporated by reference). For example, it may be advantageous to treat a patient with constant levels of antibodies with reduced affinity for CD40L for semi-prophylactic treatments. Likewise, antibodies with increased affinity for CD40L may be advantageous for short-term treatments.

Routes of Administration

The compounds of the invention may be administered in any manner which is medically acceptable. Depending on the specific circumstances, local or systemic administration may be desirable. Preferably, the compound is administered via a parenteral route such as by an intravenous, intraarterial, subcutaneous, intramuscular, intraorbital, intraventricular, intraperitoneal, subcapsular, intracranial, intraspinal, or intranasal injection, infusion or inhalation. The compound also may be administered by implantation of an infusion pump, or a biocompatible or bioerodable sustained release implant, into the recipient host, either before or after implantation of donor tissue. Alternatively, certain compounds of the invention, or formulations thereof, may be appropriate for oral or enteral administration. Still other compounds of the invention will be suitable for topical administration.

In general, compounds of the invention are administered to the recipient host. However, the compounds also can be administered to the donor, or to the donor tissue. For example, a compound of the invention can be included in a perfusion or preservative fluid in which the donor tissue is stored or transported prior to its integration into the recipient host.

Dosages and Frequency of Treatment

The amount of and frequency of dosing for any particular compound to be administered to a patient for a given immune complex disease is within the skills and clinical judgement of ordinary practitioners of the tissue transplant arts, such as transplant surgeons. The general dosage and administration regime is established by preclinical and clinical trials, which involve extensive but routine studies to determine the optimal administration parameters of the compound. Even after such recommendations are made, the practitioner will often vary these dosages for different recipient hosts based on a variety of considerations, such as the individual's age, medical status, weight, sex, and concurrent treatment with other pharmaceuticals. Determining the optimal dosage and administration regime for each anti-CD40L compound used to inhibit graft rejection is a routine matter for those of skill in the pharmaceutical and medical arts.

Generally, the frequency of dosing would be determined by an attending physician or similarly skilled practitioner, and might include periods of greater dosing frequency, such as at daily or weekly intervals, alternating with periods of less frequent dosing, such as at monthly or longer intervals.

To exemplify dosing considerations for an anti-CD40L compound, the following examples of administration strategies are given for an anti-CD40L mAb. The dosing amounts could easily be adjusted for other types of anti-CD40L compounds. In general, single dosages of between about 0.05 and about 50 mg/kg patient body weight are contemplated, with dosages most frequently in the 1-20 mg/kg range. For acute treatment, such as before or at the time of transplantation, or in response to any evidence that graft rejection is beginning, an effective dose of antibodies ranges from about 1 mg/kg body weight to about 20 mg/kg body weight, administered daily for a period of about 1 to 5 days, preferably by bolus intravenous administration. The same dosage and dosing schedule may be used in the load phase of a load-maintenance regimen, with the maintenance phase involving intravenous or intramuscular administration of antibodies in a range of about 0.1 mg/kg body weight to about 20 mg/kg body weight, for a treatment period of anywhere from weekly to 3 month intervals. Chronic treatment may also be carried out by a maintenance regimen, in which antibodies are administered by intravenous or intramuscular route, in a range of about 0.1 mg/kg body weight to about 20 mg/kg body weight, with interdose intervals ranging from about 1 week to about 3 months. In addition, chronic treatment may be effected by an intermittent bolus intravenous regimen, in which between about 1.0 mg/kg body weight and about 100 mg/kg body weight of antibodies are administered, with the interval between successive treatments being from 1 to 6 months. For all except the intermittent bolus regimen, administration may also be by oral, pulmonary, nasal or subcutaneous routes.

According to an alternate embodiment of this invention for inhibition of graft rejection, the effectiveness of the antibodies may be increased by administration serially or in combination with conventional anti-rejection therapeutic agents or drugs such as, for example, corticosteroids or immunosuppressants. Alternatively, the antibodies may be conjugated to a conventional

agent. This advantageously permits the administration of the conventional agent in an amount less than the conventional dosage, for example, less than about 50% of the conventional dosage, when the agent is administered as monotherapy. Accordingly, the occurrence of many side effects associated with that agent should be avoided.

Combination therapies according to this invention for treatment of graft rejection include the use of anti-CD40L antibodies together with agents targeted at B cells, such as anti-CD19, anti-CD28 or anti-CD20 antibody (unconjugated or radiolabeled), IL-14 antagonists, LJP394 (LaJolla Pharmaceuticals receptor blocker), IR-1116 (Takeda small molecule) and anti-Ig idiotype monoclonal antibodies. Alternatively, the combinations may include T cell/B cell targeted agents, such as CTLA4Ig, IL-2 antagonists, IL-4 antagonists, IL-6 antagonists, receptor antagonists, anti-CD80/CD86 monoclonal antibodies, TNF, LFA1/ICAM antagonists, VLA4/VCAM antagonists, brequinar and IL-2 toxin conjugates (e.g., DAB), prednisone, anti-CD3 MAb (OKT3), mycophenolate mofetil (MMF), cyclophosphamide, and other immunosuppressants such as calcineurin signal blockers, including without limitation, tacrolimus (FK506). Combinations may also include T cell targeted agents, such as CD4 antagonists, CD2 antagonists and IL-12.

For maintenance of graft integration, or in a period following suppression of an acute episode of graft rejection, a maintenance dose of anti-CD40L antibodies, alone or in combination with a conventional anti-rejection agent is administered, if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced. Where no sign of graft rejection is evident, treatment might cease, with vigilant monitoring for signs of graft rejection. In other instances, as determined by the ordinarily skilled practitioner, occasional treatment might be administered, for example at intervals of four weeks or more. Recipient hosts may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

Formulation

In general, compounds of the invention are suspended, dissolved or dispersed in a pharmaceutically acceptable carrier or excipient. The resulting therapeutic composition does not

adversely affect the recipient's homeostasis, particularly electrolyte balance. Thus, an exemplary carrier comprises normal physiologic saline (0.15M NaCl, pH 7.0 to 7.4). Other acceptable carriers are well known in the art and are described, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., 1990. Acceptable carriers can include biocompatible, inert or bioabsorbable salts, buffering agents, oligo- or polysaccharides, polymers, viscosity-improving agents, preservatives, and the like.

An anti-CD40L compound used in the methods of the invention is administered in a pharmaceutically-effective or therapeutically-effective amount, which is an amount sufficient to produce a detectable, preferably medically beneficial effect on a recipient host at risk or or afflicted with graft rejection. Medically beneficial effects would include preventing, delaying or attenuating deterioration of, or detectably improving, the recipient's medical condition. As an example, an indication of the status of a kidney allograft or xenograft, renal function and health may be monitored with one or more routine laboratory tests which measure the concentrations of relevant substances in blood or urine, other urine characteristics, or the rate of clearance of various substances from the blood into the urine. The parameters measured by these tests, either individually or in combination, can be used by a physician to assess renal function or damage. Examples of such parameters include the blood concentration of urea, creatinine or protein; the urine concentration of protein or of various blood cells such as erythrocytes or leucocytes; urine specific gravity; amount of urine; the clearance rates of inulin, creatinine, urea or p-aminohippuric acid; and the presence of hypertension or edema.

As a specific example of a clinical use of the methods of the invention, in recipients of donor kidney tissue, anti-CD40L MAb (e.g., hu5c8) is administered perioperatively or to recipients presenting with evidence of graft rejection. Acute renal allograft rejection can be manifested by numerous indicia, including increases in serum creatinine or blood urea nitrogen, reduction in urine output, development of proteinuria and/or hematuria, or other indications of graft rejection. The amount and timecourse of immunomodulatory therapy should be sufficient to produce a clinically beneficial change in one or more of these indicia. An exemplary timecourse and dosage schedule is set forth in the proof-of-principle studies included herein.

Essentially, however, the therapy involves administration of a CD40:CD154 binding interruptor (exemplified by hu5c8) intravenously as a bolus therapy in amounts up to 50 mg/kg, followed by an appropriate regime of subsequent administrations (e.g., daily intravenous or subcutaneous injections) for up to two weeks following initiation of therapy, or until evidence is obtained of the desired beneficial change in indicia of graft rejection or failure.

As another example, for recipients with evidence of other organ rejection, an anti-CD40L compound would be administered in a similar fashion as that described above. For example, acute rejection of liver transplants leads to jaundice (hyperbilirubinemia), hepatitis (increased aminotransferase levels), coagulopathy and encephalopathy.

Pre-Clinical Model Systems for Evaluating CD40:CD154 Interruptor Treatment Regimes

A preferred, exemplary model system for testing efficacy of a CD40:CD154 interrupting compound (e.g., an anti-CD40L compound, such as the mAb 5c8) is the primate renal allograft model disclosed in prior related U.S. Provisional S.N. 60/049,389 (06/11/97) and in Kirk et al. (1997), 94 Proc. Natl. Acad. Sci. USA 8789-8794, the teachings of both which are incorporated by reference herein. The present rhesus monkey model has been shown repeatedly to be a rigorous test of immune manipulation: one that is exquisitely sensitive to even minor changes in allograft function or adverse effects on recipient wound healing and immune system function. In addition, it has obvious biological similarity to human renal transplantation. Specifically, genes that encode MHC proteins are well conserved between rhesus monkeys and humans, and their rejection of vascularized organs closely parallels that seen clinically.

It will be readily appreciated that this model system is suitable for evaluating grafts comprising renal (kidney) tissue. Other art-recognized preclinical model systems, preferably in primates, are suitable for assessing efficacy of other graft tissue types such as liver, heart, lung, pancreas, pancreatic islet, skin, peripheral or central nerve, or other tissue or organ types.

Materials and Methods

Reagents

Human CTLA4-Ig and a control fusion protein-IgG1 were prepared as previously described and shipped in solution by Genetics Institute, Cambridge, MA. The anti-CD40 ligand antibody, humanized 5c8, was prepared as previously described and shipped in solution by Biogen Corporation, Cambridge, MA. The hamster anti-mouse CD28 monoclonal antibody PV-1 (IgG1, clone G62) was purified from hybridoma culture supernatants and used as an isotype control monoclonal antibody.

MHC Typing and Donor/Recipient Selection

Donor-recipient combinations and animals chosen for third party cells were selected based on genetic non-identity at both MHC class I and class II. Class I disparity was established by one-dimensional isoelectric focusing as previously described. Class II disparity was established based on the results of unidirectional mixed lymphocyte reactions (MLRs). In addition, the animal's DRB loci were verified to be disparate by denaturing gradient gel electrophoresis and direct sequencing of the second exon of DRB as previously described. Vigorous T cell responsiveness of the recipient towards the donor was confirmed in vitro for all donor-recipient pairs. The experiments described in this study were conducted according to the principles set forth in the "Guide for the Care and Use of Laboratory Animals" Institute of Laboratory Animals Resources, National Research Council, DHHS, Pub. No. NIH 86-23(1985).

In Vitro Cellular Analysis

Unidirectional MLRs were performed on all animals prior to transplantation and on rejection free survivors after 100 days. Each animal was tested against all potential donors to establish the highest responder pairs for transplantation. Responder cells (3×10^5) were incubated with irradiated stimulator cells (1×10^5) at 37°C for 5 days. Cells were pulse-labeled with 3H-thymidine and proliferation was monitored by 3H-thymidine incorporation. Polyclonal stimulation with Concanavilin A (25 mcg/ml) served as a positive control. A stimulation index was calculated by normalization to self reactivity, which in all cases was near background

incorporation. For in vitro dose response studies, CTLA4-Ig or humanized 5c8 was added to the MLR on day 1 at concentrations ranging from 100 mcg/ml to 0.01 mcg/ml. Combined treatments were performed by varying the CTLA4-Ig concentration and holding the humanized 5c8 concentration steady at 50 mcg/ml.

Peripheral blood lymphocyte phenotype analysis was performed prior to transplantation and periodically during and after drug therapy. Assays evaluated 0.2 ml of heparinized whole blood diluted with phosphate buffered saline and 1% fetal calf serum. FITC labeled T11, B1 (Coulter), and FN18 (the generous gift of Dr. David M. Neville, Jr.) monoclonal antibodies were used to assess the percentage of CD2 (T cell/NK cell), CD20 (B cell), and CD3 (T cell) positive cells respectively. Red blood cells were removed from the preparation by ACK lysis buffer (0.15 M NH₄Cl, 1.0 mM KHCO₃, 0.1 mM Na₂EDTA, pH 7.3) treatment following staining. Cells were subjected to flow cytometry immediately, or following fixation in 1% paraformaldehyde. Flow cytometry was performed using a Becton Dickinson FACSCAN.

Renal Allografts

Renal allotransplantation was performed as previously described. Briefly, outbred juvenile (1 to 3 years of age) rhesus monkeys, seronegative for simian immunodeficiency virus, simian retrovirus, and herpes B virus, were obtained from the Primate Center (University of Wisconsin) or LABS (Yemassee, SC). Procedures were performed under general anesthesia using ketamine (1 mg/kg, i.m.), xylazine (1 mg/kg, i.m.) and halothane (1%, inhaled). Transplantation was performed between genetically distinct donor-recipient pairs as determined by the MHC analysis described above. The animals were heparinized during organ harvest and implantation (100 units/kg). The allograft was implanted using standard microvascular techniques to create an end to side anastomosis between the donor renal artery and recipient distal aorta as well as the donor renal vein and recipient vena cava. A primary ureteroneocystostomy was then created. Bilateral native neplirectomy was completed prior to closure.

Animals were treated with intravenous fluid for approximately 36 hours until oral intake was adequate. Trimethoprim-sulfa was administered for 3 days for surgical antibiotic prophylaxis. Each animal received 81 mg of aspirin on the day of surgery. The need for analgesia was assessed frequently and analgesia was maintained with intramuscular butorphanol. Animals were weighed weekly. Skin sutures were removed after 7 to 10 days. CTLA4-Ig and/or humanized 5c8 were given intravenously at doses and dosing schedules varying based on accumulating experience with the agents. No other immunopharmaceuticals were administered. Serum creatinine, and whole blood electrolytes (Na⁺, K⁺, Ca²⁺) and hemoglobin were determined every other day until stable and then weekly.

Pathological Analysis

Biopsies were performed on animals suspected of having rejection using a 20-gauge needle core device (Biopty-Cut, Bard). Standard staining with hematoxylin and eosin was performed on frozen or formalin fixed tissue to confirm the diagnosis of rejection. Animals were euthanized at the time of anuria or if a weight loss of 15% of pre-transplant body weight occurred in accordance with AAALAC standards. All animals underwent complete gross and histopathological evaluation at the time of death.

Results

Both CTLA4-Ig and humanized 5c8 inhibited rhesus MLRs in a dose dependent fashion. CTLA4-Ig was, however, more effective than humanized 5c8 as a single agent in preventing T cell proliferation. Substantial reduction in thymidine incorporation was seen at a CTLA4-Ig concentration of 0.1 mcg/ml, and further inhibition was achieved at higher concentrations. Modest reduction in proliferation was achieved with humanized 5c8 concentrations of 0.01 mcg/ml, but inhibition was not substantially improved by increasing concentrations. When tested in combination, both agents together inhibited proliferation approximately 100 times more effectively than did either agent alone. Dose response studies were repeated for 3 separate naive animals with identical results. CTLA4-Ig and humanized 5c8 therefore *synergistically* prevent allograft rejection in vivo.

Twelve renal allotransplants were performed. Four animals received transplants without any immunological intervention. These animals rejected in 5, 7, 7 and 8 days. Histological examination of their kidneys showed acute cellular rejection characterized by diffuse interstitial and tubular lymphocytic infiltration with edema and cellular necrosis. One animal was given a 5-day course of CTLA4-Ig (10 mg/kg/d) beginning at the time of transplantation and had graft survival prolonged to 20 days. Graft loss was due to cellular rejection indistinguishable from that seen in the control animals. One animal was treated with CTLA4-Ig 20 mg/kg on the day of transplantation, followed by a 12 day course of 10 mg/kg every other day and had graft survival prolonged to 30 days. Again, graft loss was due to acute cellular rejection. Extrapolating from previously published work in a rat heterotopic cardiac allograft model, a donor specific transfusion of lymph node derived lymphocytes (10^8) was given at the time of transplantation to these 2 animals.

Two animals were treated with humanized 5c8 alone. Both animals received 20 mg/kg every other day beginning on the day of surgery and continuing for 14 post-operative days (8 doses total). Both animals experienced extended rejection free survival, although transient creatinine elevations were recorded during the second and forth post-operative weeks. Both animals rejected between 95 and 100 days post-transplant. Biopsy was performed on each animal to confirm the diagnosis. Both animals were then re-treated with 7 doses of humanized 5c8 (20 mg/kg; one animal every other day and one animal daily) and both returned to normal graft function with no demonstrable adverse effects. They remained alive and well greater than 150 days after transplantation.

Two animals were given 20mg/kg each of CTLA4-Ig and humanized 5c8 following transplantation. Again, each drug was given every other day beginning on the day of surgery and continuing for 14 post-operative days. One animal rejected 32 days after surgery. The other remained free of rejection for 100 days, but like those animals treated with humanized 5c8 alone, rejected at that time. Similarly, a biopsy showed acute cellular rejection. The initial regimen of CTLA4-Ig and humanized 5c8 was repeated and the animal's creatinine level returned to baseline (1.0). MLR analysis following this treatment showed a donor specific loss of reactivity. Third

party responsiveness was maintained. At 165 days post transplant, the animal was sacrificed as required by protocol due to weight loss. Graft function at that time was normal. At autopsy, the animal was found to have *Shigella* and *Camphylobacter* enterocolitis, a common infection in rhesus monkeys. This illness had infected multiple animals in the original primate colony, including several untreated animals. No other pathological abnormality was found; specifically, there was no evidence of lymphoproliferative disease or opportunistic infection. Histologically, the graft had isolated nests of lymphocytes in the interstitium, but no evidence of tubular infiltration, glomerular damage, or parenchymal necrosis.

Like the animals treated with humanized 5c8 alone, both of these animals had transient increases in their creatinine combined with an increase in graft size during the fourth post-operative week. It was hypothesized that this graft swelling reflected a second wave of infiltrating lymphocytes and therefore led to a modified dosage schedule such that both reagents were given on the day of surgery and on post-operative days 2, 4, 6, 8, 12, 16, and 28.

Two animals were treated with this modified regimen. Both have experienced rejection free survival, free of illness or alterations in renal functions for greater than 150 days. After 100 days of rejection free survival, MLRs were repeated against donor cells and third party cells. No changes in in vitro reactivity were observed. These studies were repeated after 150 days of rejection free survival with identical results. Both animals maintained vigorous in vitro responses toward donor and third party cells but failed to reject their allografts. No animal has demonstrated toxicity from any of the therapies employed. Specifically, there has been no fever, anorexia, or hemodynamic abnormalities, and no opportunistic infections have occurred. Animals have been housed in standard conditions and have been allowed contact with the other animals in the colony. They have maintained normal weight gain. Laboratory chemistries and hematological parameters such as hemoglobin and white blood cell counts have remained normal. The percentages of cells expressing CD2, CD3 and CD20 were unaffected by any treatment regimen. Specifically, no reduction in T cell counts was observed during or after treatment in any animal.

Further Pre-Clinical Studies using the Primate Renal Allograft Model System

The above-described primate renal allograft system was used subsequently to test various additional and/or further refined therapeutic regimes based on the use of humanized mAb 5c8 as a monotherapy, or in combination with another therapeutic agent, e.g., CTLA4-Ig, MMF, tacrolimus, corticosteroids or a combination thereof.

Monotherapy for Renal Allograft in Primates

Two animals received 5c8 monotherapy using an induction and maintenance regime as follows: The induction schedule involved administration of 20 mg/kg 5c8 at study days -1, 0, 3, 10 and 18, with day 0 being the day of renal allotransplantation surgery. Maintenance involved monthly administration of 20 mg/kg 5c8, beginning on study day 28. The treated animals remained essentially free of graft rejection, assessed by monitoring lymphocyte subset counts and/or serum creatinine level, as of study days 170 and 163, respectively.

Two additional animals received 5c8 monotherapy using a standard induction and low-dose maintenance regime as follows: The induction schedule involved administration of 20 mg/kg 5c8 at study days -1, 0, 3, 10 and 18, with day 0 being the day of renal allotransplantation surgery. Maintenance involved monthly administration of 10 mg/kg 5c8, beginning on study day 28. The treated animals remained essentially free of graft rejection as of study days 149 and 148, respectively.

Two further animals received 5c8 monotherapy using a low-dose induction and low-dose maintenance regime as follows: The induction schedule involved administration of 10 mg/kg 5c8 at study days -1, 0, 3, 10 and 18, with day 0 being the day of renal allotransplantation surgery. Maintenance involves monthly administration of 10 mg/kg 5c8, beginning on study day 28. The treated animals remain essentially free of graft rejection as of study days 38 and 9, respectively.

Yet two further animals received 5c8 monotherapy using a lower-dose induction and lower-dose maintenance regime as follows: The induction schedule involved administration of 5 mg/kg 5c8 at study days -1, 0, 3, 10 and 18, with day 0 being the day of renal allotransplantation

surgery. Maintenance involves monthly administration of 5 mg/kg 5c8, beginning on study day 28. The treated animals rejected the renal implants at study days 7-10.

Combination Therapies for Renal Allograft in Primates

All animals received 5c8 therapy using the standard 20 mg/kg induction and 20 mg/kg maintenance regime described above, in combination with other immunosuppressive therapeutic regimes as follows: Three animals received combination therapy involving corticosteroids (e.g., methylprednisolone, using a 5 day induction course) and mycophenolate mofetil (MMF; 20 mg/kg po BID) at therapeutically effective doses. The treated animals remained essentially free of graft rejection as of study days 143, 81 and 80, respectively. In contrast, one control animal treated with similar doses of MMF and corticosteroids in the absence of 5c8 therapy rejected the renal implant at study day 7.

Two additional animals received combination therapy involving the immunosuppressant tacrolimus (formerly FK506) at therapeutically effective doses (1.5-2 mg/kg po BID, target trough 10 ng/ml). These treated animals remained essentially free of graft rejection as of study days 31 and 36, respectively.

Two further animals received combination therapy involving CTLA4-Ig at therapeutically effective doses. These treated animals remained essentially free of graft rejection at study days 122 and 3, respectively.

Conclusion based on Preclinical Model Studies

The above-described results, taken together, indicate that induction of graft integration with the CD40:CD154 binding interruptor humanized 5c8 alone can lead to long-term survival of allografted tissue. The effects of humanized 5c8 combine synergistically with the effects of a CD28 signalling interruptor, CTLA4-Ig, and are compatible with several known immunosuppressants and/or immunomodulatory agents.

Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative of, rather than limiting on, the invention disclosed herein. Scope of the invention thus is indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

What is claimed is:

1. A method of inhibiting rejection of a tissue graft by a graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient.
2. A method according to claim 1, wherein the CD40:CD154 binding interruptor is an anti-CD40L (anti-CD154) compound.
3. A method according to claim 2, wherein the anti-CD40L compound is a monoclonal antibody.
4. A method according to claim 3, wherein the monoclonal antibody binds to the 5c8 antigen.
5. A method according to claim 4, wherein the monoclonal antibody has the antigen-specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916.
6. A method of reversing acute rejection of grafted tissue in a graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient.
7. A method according to claim 6, wherein the grafted tissue is selected from renal, hepatic, cardiac, pancreatic, skin, vascular, nerve, bone and cartilage tissue.
8. A method of prolonging survival of grafted tissue in a graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient.
9. A method of attenuating immunological complications of failure of grafted tissue in a graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient.
10. A method according to claim 1, 6, 8 or 9, wherein the grafted tissue is allogeneic to the graft recipient.

11. A method according to claim 1, 6, 8 or 9, wherein the grafted tissue is xenogeneic to the graft recipient.
12. A method according to claim 1, 6, 8 or 9, comprising the additional step of administering an effective amount of an immunosuppressive or immunomodulatory compound to the graft recipient.
13. A method according to claim 12 wherein the immunosuppressive or immunomodulatory compound is an agent that interrupts T cell costimulatory signalling via CD28.
14. A method according to claim 12 wherein the immunosuppressive or immunomodulatory compound is an agent that interrupts calcineurin signalling.
15. A method according to claim 14 wherein the agent is selected from cyclosporine and tacrolimus.
16. A method according to claim 12 wherein the immunosuppressive or immunomodulatory compound is a corticosteroid or an antiproliferative agent.
17. A method according to claim 12 wherein the immunosuppressive or immunomodulatory compound is selected from: sirolimus, mycophenolate mofetil, mizorubine, deoxyspergualin, brequinar sodium, leflunomide, and azaspirane.
18. A method of inhibiting rejection of a tissue graft by a graft recipient, comprising the steps of implanting a tissue graft into the graft recipient; and, administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient on days 2, 4, 6, 8, 12, 16, and 28, counted from the day of implantation.
19. A method of inhibiting rejection of a tissue graft by a graft recipient, comprising the steps of: administering an effective amount of a CD40:CD154 binding interruptor to a prospective graft recipient; one day thereafter, implanting a tissue graft into the graft recipient and concomitantly administering an effective amount of the CD40:CD154 binding interruptor to the recipient; and, administering effective amounts of the

CD40:CD154 binding interruptor to the recipient on days 3, 10, 18, and 28, counted from the day of implantation.

20. A method according to claim 19, comprising the additional step of repeating administration of an effective amount of the CD40:CD154 binding interruptor to the recipient on a monthly basis, beginning one month after day 28, as counted from the day of implantation.
21. A method of reversing acute rejection of grafted tissue in a graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to the graft recipient on the day on which the recipient presents indicia of acute graft rejection, and on days 3, 10, 18, and 28 thereafter.
22. A method according to claim 21, comprising the additional step of repeating administration of an effective amount of the CD40:CD154 binding interruptor to the recipient on a monthly basis, beginning one month after day 28, as counted from the day of presentation with indicia of acute graft rejection.
23. A composition comprising: a CD40:CD154 (CD40L) binding interruptor; and, an immunosuppressive or immunomodulatory compound.
24. A composition according to claim 23, wherein the CD40:CD154 (CD40L) binding interruptor is a monoclonal antibody having the antigen-specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916; and, the immunosuppressive or immunomodulatory compound is an agent that interrupts T cell costimulatory signalling via CD28.
25. A composition according to claim 23, wherein the CD40:CD154 (CD40L) binding interruptor is a monoclonal antibody having the antigen-specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916; and, the immunosuppressive or immunomodulatory compound is an agent that interrupts calcineurin signalling.

26. A composition according to claim 25, wherein the immunosuppressive or immunomodulatory compound is tacrolimus.
27. A composition according to claim 23, wherein the CD40:CD154 (CD40L) binding interruptor is a monoclonal antibody having the antigen-specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916; and, the immunosuppressive or immunomodulatory compound is a corticosteroid or an antiproliferative agent.
28. A composition according to claim 23, wherein the CD40:CD154 (CD40L) binding interruptor is a monoclonal antibody having the antigen-specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916; and, the immunosuppressive or immunomodulatory compound is selected from: sirolimus, mycophenolate mofetil, mizorubine, deoxyspergualin, brequinar sodium, leflunomide, and azaspirane.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/395 A61K38/17 A61K31/57 A61K31/445 A61K38/13
 //(A61K39/395, 38:13), (A61K39/395, 31:57), (A61K39/395, 31:445),
 (A61K38/17, 38:13), (A61K38/17, 31:57), (A61K38/17, 31:445)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 474 771 A (CHESS LEONARD ET AL) 12 December 1995 cited in the application see column 7, line 45 - line 51 see column 11, line 29-32 see column 11, line 65 - column 12, line 1 see claims	1-10, 18-22
Y		12, 15-17, 23, 24, 26-28

	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "Z" document member of the same patent family

Date of the actual completion of the international search

19 August 1998

Date of mailing of the international search report

01/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Covone, M

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/US 98/10075

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>FOY T M ET AL.: "IN VIVO CD40-GP39 INTERACTIONS ARE ESSENTIAL FOR THYMUS-DEPENDENT HUMORAL IMMUNITY II. PROLONGED SUPPRESSION OF THE HUMORAL IMMUNE RESPONSE BY AN ANTIBODY TO THE LIGAND FOR CD40, GP39" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 178, no. 5, November 1993, pages 1567-1575, XP000647639 see page 1574, right-hand column, line 20 - line 44 see title</p>	<p>1-3, 6-13, 18-23</p>
Y		
X	<p>ELWOOD E.T. ET AL.: "Long-term murine skin allograft survival with perioperative CTLA4-Ig and anti-gp39: the role of CD4+ T cells" SURGICAL FORUM, vol. 47, 1996, pages 427-429, XP002074813 see the whole document</p>	<p>24 1-3, 6-10,12, 13,18-23</p>
X	<p>LARSEN C.L. ET AL.: "CD40-gp39 interactions play a critical role during allograft rejection" TRANSPLANTATION, vol. 61, no. 1, 15 January 1996, pages 4-9, XP002074814 see section Results and Discussion</p>	<p>1-3, 6-10,12, 13,15, 16,18-23</p>
Y	<p>PATENT ABSTRACTS OF JAPAN vol. 095, no. 001, 28 February 1995 & JP 06 298654 A (SUMITOMO ELECTRIC IND LTD), 25 October 1994 see abstract</p>	<p>12, 15-17, 23,26-28</p>
A		
P,X	<p>WO 97 34633 A (SQUIBB BRISTOL MYERS CO) 25 September 1997 see page 3, line 13 - line 19 see page 9, line 9 - line 15 see page 13; line 18 - line 23 see claims 44,47,48 see figures 2D,8A</p>	<p>14,25 1-3, 6-13, 18-23</p>
E,L	<p>WO 98 30241 A (BIOGEN INC ;KALLED SUSAN L (US); THOMAS DAVID W (US)) 16 July 1998 see page 1, line 30 - page 3, line 12 see page 10, line 23 - page 11, line 5 see claims 9,13-24 This document casts doubt on the priority of the underlying application, is of the same applicant and contains novelty destroying subject matter.</p>	<p>1-13,16, 18-24,27</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/10075

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-22
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10075

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5474771	A	12-12-1995	AU 675922 B	27-02-1997
			AU 3141993 A	15-06-1993
			CA 2123224 A	27-05-1993
			EP 0614374 A	14-09-1994
			JP 7505761 T	29-06-1995
			WO 9309812 A	27-05-1993
WO 9734633	A	25-09-1997	AU 2331097 A	10-10-1997
WO 9830241	A	16-07-1998	NONE	